# B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis

> **NCT06612411** · EARLY_PHASE1 · RECRUITING · sponsor: **Jinling Hospital, China** · enrollment: 180 (estimated)

## Conditions studied

- Irritable Bowel Syndrome with Diarrhea
- Purine Metabolism Disorder

## Interventions

- **DRUG:** B. subtilis
- **DRUG:** Dead B. subtilis

## Key facts

- **NCT ID:** NCT06612411
- **Lead sponsor:** Jinling Hospital, China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06612411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06612411, "B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06612411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*